Mei Li M. Kwong

Mei Li M. Kwong

Auto-generated profile, based on publicly available information

Mei Li M. Kwong

Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2017 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
DDDrew C. Deniger
Drew C. Deniger
MKMei Li M. Kwong
Mei Li M. Kwong
APAnna Pasetto
Anna Pasetto
MDMark E. Dudley
Mark E. Dudley
JWJohn R. Wunderlich
John R. Wunderlich
SRSteven A. Rosenberg
Steven A. Rosenberg
Purpose: This pilot feasibility clinical trial evaluated the coadministration of vemurafenib, a small-molecule antagonist of BRAFV600 mutations, and tumor-infiltrating lymphocytes (TIL) for the treatment of metastatic melanoma. Experimental Design: A metastatic tumor was resected for growth of TILs, and patients were treated with vemurafenib for 2 weeks, followed by resection of a second lesion. Patients then received a nonmyeloablative preconditioning regimen, infusion of autologous TILs, and high-dose interleukin-2 administration. Vemurafenib was restarted at the time of TIL infusion and was continued for 2 years or until disease progression. Clinical responses were evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0. Metastases resected prior to and after 2 weeks of vemurafenib were compared using TCRB deep sequencing, immunohistochemistry, proliferation, and recognition of autologous tumor. Results: The treatment was well tolerated and had a safety profile similar to that of TIL or vemurafenib alone. Seven of 11 patients (64%) experienced an objective clinical response, and 2 patients (18%) had a complete response for 3 years (one response is ongoing at 46 months). Proliferation and viability of infusion bag TILs and peripheral blood T cells were inhibited in vitro by research-grade vemurafenib (PLX4032) when approaching the maximum serum concentration of vemurafenib. TCRB repertoire (clonotypes numbers, clonality, and frequency) did not significantly change between pre- and post-vemurafenib lesions. Recognition of autologous tumor by T cells was similar between TILs grown from pre- and post-vemurafenib metastases. Conclusions: Coadministration of vemurafenib and TILs was safe and feasible and generated objective clinical responses in this small pilot clinical trial. Clin Cancer Res; 23(2); 351–62. ©2016 AACR. See related commentary by Cogdill et al., p. 327

16 July 2024 in The Oncologist
Verified
Journal Article
Open access
PDF file
MKMei Li M Kwong
Mei Li M Kwong
JYJames C Yang
James C Yang
The availability of the T-cell growth factor, interleukin-2, was essential to the study of T-cell biology. It became available in recombinant form in 19841 and by 1985, it was being applied to the production of antitumor T cells for therapy in murine models. Simply placing enzymatically dispersed murine or human tumors into human IL-2 led to the rapid outgrowth of what have become known as tumor-infiltrating lymphocytes (TIL).2 This outgrowth coincided with the rapid destruction of the cocultured tumor cells in vitro, leading to a pure preparation of expanding T lymphocytes. At first, these were empirically tested against tumors in murine models using adoptive cell transfer.3 Brief support with systemic IL-2 was also given with the TIL to enhance their survival in vivo. TIL proved to be highly effective against early micrometastases at lower doses than nonspecific antitumor cells such as lymphokine-activated killer cells (LAK). It was also noted that the addition of high-dose cyclophosphamide or whole-body radiation prior to TIL administration was able to cause the regression of much larger established tumors in mice. Early clinical trials with TIL in patients began in 1988.4 These showed that TIL and IL-2 alone had modest activity, but the addition of pretreatment with cyclophosphamide and the later addition of fludarabine to lymphodeplete the recipient could cause durable major regressions in patients with melanoma.5

1 August 2025 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PMPaul Hsin-ti McClelland
Paul Hsin-ti McClelland
SNShirley K. Nah
Shirley K. Nah
AGAlexandra M. Gustafson
Alexandra M. Gustafson
ADAaron J. Dinerman
Aaron J. Dinerman
BWBradley S. White
Bradley S. White
NKNicholas D. Klemen
Nicholas D. Klemen
PURPOSE: Acral lentiginous melanoma is a subtype of cutaneous melanoma arising from palmar, plantar, or subungual skin. These tumors are characterized by aggressive biology, a low tumor mutational burden (TMB), and diminished sensitivity to immune checkpoint blockade. It is unknown whether adoptive cell transfer of tumor-infiltrating lymphocytes (ACT-TIL) has efficacy in patients with acral melanoma. METHODS: We analyzed prospectively collected data from 442 patients with metastatic cutaneous melanoma who were treated on clinical trials of ACT-TIL at a single institution between 1999 and 2018. Although blinded to treatment outcome and genomic data, we retrospectively identified patients who had acral subtype on the basis of clinicopathologic data available at the time of diagnosis. We then evaluated the ACT-TIL treatment outcomes of patients with acral melanoma and compared them with contemporaneously treated patients with nonacral melanoma. RESULTS: Out of 442 included patients, 30 (7%) had acral melanoma while 412 (93%) had nonacral melanoma. Cohorts had similar clinical characteristics, protocol enrollment, and treatment-related factors. The objective response rate to ACT-TIL in patients with acral and nonacral melanomas was 43% and 40%, respectively ( P = .87), with 3% and 16% having complete responses (CRs; P = .07). Median progression-free survival was 3.5 and 4.1 months ( P = .40) and median overall survival was 13 and 17 months ( P = .79), respectively. Acral melanomas had lower TMB and ultraviolet mutational signature scores than nonacral melanomas. CONCLUSION: ACT-TIL can mediate objective responses in patients with metastatic acral melanoma, and outcomes in patients with acral disease were unexpectedly comparable with those of contemporaneously treated patients with nonacral cutaneous melanoma. Further research is necessary to understand the immunologic basis of responses to ACT-TIL in acral melanoma and to increase the frequency of CRs.

14 June 2020 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
ACAudrey H. Choi
Audrey H. Choi
CFCyrus Farzaneh
Cyrus Farzaneh
NKNidhi Kejriwal
Nidhi Kejriwal
ACAashna Calidas
Aashna Calidas
KCKathia Cordero-Caban
Kathia Cordero-Caban
MSMaheswari Senthil
Maheswari Senthil

1 January 2019 in Case Reports in Surgery
Verified
Journal Article
Open access
PDF file
MKMei Li M Kwong
Mei Li M Kwong
JPJeffrey Pelton
Jeffrey Pelton
Hepatic artery variations occur in about one‐fourth of the population, are frequent questions on standardized surgery exams, and are often discussed on teaching rounds with an attending surgeon. Intraoperatively, it is important to be aware of possible vascular anomalies in order to prevent ligation or injury of an essential vessel. This case report describes an extremely rare vascular anomaly encountered during a pancreaticoduodenectomy (Whipple operation). Our patient was a middle‐aged woman who was incidentally diagnosed with a cystic pancreatic lesion. During the operation, an aberrant middle colic artery was found to be originating from the gastroduodenal artery instead of its usual origin at the superior mesenteric artery. This anomalous middle colic artery has not been previously reported in a live patient. It underscores the importance of being aware of possible vascular variations that may be encountered intraoperatively in order to prevent morbidity and mortality.

3 August 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
KHKyle J. Hitscherich
Kyle J. Hitscherich
ADAaron J. Dinerman
Aaron J. Dinerman
AHAbraham A. Hakim
Abraham A. Hakim
VDVictoria Dulemba
Victoria Dulemba
SSSivasish Sindiri
Sivasish Sindiri
FLFrank J. Lowery
Frank J. Lowery
Adoptive cell transfer of tumor infiltrating CD4 + T cells or T cells genetically modified to express antitumor CD4 + T cell receptors (TCRs) has shown clinical efficacy in patients with advanced solid tumors. We previously defined unique transcriptomic states of antitumor, neoantigen-specific CD8 + and CD4 + tumor infiltrating lymphocytes (TIL) in human cancer. However, optimal cell surface protein markers that identify and would enable viable cell isolation and selective enrichment of antitumor CD4 + T cells have yet to be identified. Here, we define transcriptomic and corresponding cell surface protein profiles of antitumor CD4 + TIL within metastatic colorectal tumors using high dimensional single cell transcriptomic and proteomic analysis. Comprehensive analysis of 45 antitumor CD4 + TCR clonotypes demonstrated uniquely high cell surface protein expression of ADGRG1, CD86, and CD57. In all samples containing tumor neoantigen-reactive CD4 + TIL clonotypes, ADGRG1- and CD86-based cell surface enrichment of known reactive TCR clonotypes were 11-fold and 9-fold higher than bulk CD4 + TIL, respectively. ADGRG1- and CD86-based cell surface enrichment identified >60 validated antitumor CD4 + TCR-clonotypes including tumor organoid-reactive TCRs, as well as neoantigen-specific TCRs targeting private tumor mutations and cancer driver mutations. While both ADGRG1 and CD86 enriched CD4 + TIL displayed an exhausted neoantigen-specific gene expression signature, CD86 also enriched for cytotoxic CD4 + TIL phenotypes. CD4 + TIL isolated based on ADGRG1 expression and expanded in vitro also demonstrated neoantigen reactivity in two samples. Thus, ADGRG1 and CD86 appear to be effective protein markers for isolating human tumor-specific CD4 + TCR clonotypes and studying antitumor CD4 + TIL.